has been spoken of even more glowingly and there is accumulating evidence to suggest that it is somewhere between 25 and 50 per cent more efficient than sulphanilamide. Its cost, however, is such that it is far beyond the financial reach of dispensary patients. To date, only sulphanilamide and sulphapyridine are on the market. It is earnestly to be hoped that a way may be found to reduce the price so that both the poor and the near poor may share the benefits.
At least two of the other sulphonamides now being experimentally used for gonorrhoea have 
